Key Points
- Director Gary Pace bought 30,000 shares of Cardiff Oncology at an average price of $1.22, spending $36,600 and lifting his holdings by 2.26% to 1,356,376 shares.
- Cardiff Oncology’s stock was trading near $1.30, close to its 12-month low of $1.16 and well below its 12-month high of $4.55, reflecting continued weakness in the share price.
- The company recently posted weaker-than-expected quarterly results, with a loss of $0.18 per share and revenue of $0.04 million, while analysts currently rate the stock a consensus Hold with an average target price of $8.75.
Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) CEO Mani Mohindru bought 24,703 shares of the firm's stock in a transaction dated Thursday, June 18th. The stock was bought at an average cost of $1.21 per share, with a total value of $29,890.63. Following the transaction, the chief executive officer directly owned 24,703 shares of the company's stock, valued at approximately $29,890.63. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.
Cardiff Oncology Stock Performance
CRDF stock opened at $1.30 on Tuesday. The firm has a market cap of $88.88 million, a P/E ratio of -1.94 and a beta of 1.36. Cardiff Oncology, Inc. has a 1 year low of $1.16 and a 1 year high of $4.55. The stock has a 50-day simple moving average of $1.62 and a 200-day simple moving average of $1.97.
Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.05). The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.09 million. Cardiff Oncology had a negative return on equity of 95.51% and a negative net margin of 8,527.43%. On average, equities research analysts predict that Cardiff Oncology, Inc. will post -0.66 EPS for the current year.
Wall Street Analyst Weigh In
CRDF has been the topic of a number of recent research reports. Piper Sandler reduced their target price on shares of Cardiff Oncology from $10.00 to $6.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 25th. Craig Hallum downgraded shares of Cardiff Oncology from a "buy" rating to a "hold" rating and set a $2.00 price target on the stock. in a research note on Wednesday, June 3rd. Wall Street Zen lowered shares of Cardiff Oncology from a "hold" rating to a "sell" rating in a report on Saturday, May 16th. TD Cowen cut shares of Cardiff Oncology from a "buy" rating to a "hold" rating in a research report on Monday, June 1st. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Cardiff Oncology in a research note on Monday, May 18th. Three investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $8.75.
Check Out Our Latest Report on CRDF
Institutional Trading of Cardiff Oncology
A number of hedge funds have recently made changes to their positions in CRDF. Franklin Resources Inc. bought a new stake in shares of Cardiff Oncology in the fourth quarter worth $3,388,000. Laurion Capital Management LP boosted its stake in Cardiff Oncology by 37.2% during the 3rd quarter. Laurion Capital Management LP now owns 2,465,872 shares of the company's stock valued at $5,080,000 after acquiring an additional 668,590 shares during the last quarter. Acorn Capital Advisors LLC grew its holdings in Cardiff Oncology by 39.3% during the 3rd quarter. Acorn Capital Advisors LLC now owns 1,962,084 shares of the company's stock worth $4,042,000 after acquiring an additional 553,317 shares in the last quarter. Millennium Management LLC increased its position in shares of Cardiff Oncology by 441.5% in the 4th quarter. Millennium Management LLC now owns 194,420 shares of the company's stock worth $546,000 after purchasing an additional 158,519 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Cardiff Oncology by 7.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,498,838 shares of the company's stock worth $4,723,000 after purchasing an additional 104,409 shares during the last quarter. Institutional investors and hedge funds own 16.29% of the company's stock.
Cardiff Oncology Company Profile
(
Get Free Report)
Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.
Cardiff's pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
